Binding characteristics and tumor targeting of a covalently linked divalent CC49 single‐chain antibody

Multivalency is a recognized means of increasing the functional affinity of single‐chain Fvs (scFvs) for optimizing tumor uptake. A unique divalent single‐chain Fv protein [sc(Fv)2], based on the variable regions of the monoclonal antibody (MAb) CC49, has been generated that differs from other dimeric single‐chain constructs in that a linker sequence (L) is encoded between the repeated VL and VH domains (VL‐L‐VH‐L‐VL‐L‐VH). This construct was expressed in soluble form in Escherichia coli and purified by ion‐exchange and gel‐filtration chromatography. Purity and immunoreactivity were determined by SDS‐PAGE, HPLC and competitive RIA. sc(Fv)2 exhibited a relative KA (3.34 × 107 M−1) similar to that of the native IgG (1.14 × 108 M−1) as determined by BIAcore analysis. Pharmacokinetic studies showed rapid blood clearance for sc(Fv)2, with a T1/2 less than 40 min. Whole‐body clearance analysis also revealed rapid clearance, suggesting no significant retention in the extravascular space or normal tissues. Biodistribution studies of radiolabeled sc(Fv)2 showed tumor uptake greater than 6% ID/g after 30 min, which remained at this level for 6 hr. High tumor uptake and retention of sc(Fv)2 coupled with rapid blood and whole‐body clearance makes this dimeric scFv of MAb CC49 a strong candidate for imaging and therapeutic applications. Int. J. Cancer 81:911–917, 1999. © 1999 Wiley‐Liss, Inc.

[1]  P. Iliades,et al.  Triabodies: single chain Fv fragments without a linker form trivalent trimers , 1997, FEBS letters.

[2]  L L Houston,et al.  Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. , 1993, Cancer research.

[3]  F. Karush AFFINITY AND THE IMMUNE RESPONSE * , 1970, Annals of the New York Academy of Sciences.

[4]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Kuroki,et al.  Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. , 1988, Cancer research.

[6]  T. Yokota,et al.  Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. , 1993, Cancer research.

[7]  J. Tso,et al.  Formation of a bispecific antibody by the use of leucine zippers. , 1992, Journal of immunology.

[8]  K. D. Hardman,et al.  In vivo tumor targeting of a recombinant single-chain antigen-binding protein. , 1990, Journal of the National Cancer Institute.

[9]  M. Whitlow,et al.  Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. , 1994, Protein engineering.

[10]  R. Webster,et al.  Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer. , 1997, Protein engineering.

[11]  S. Batra,et al.  Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis. , 1999, Nuclear medicine and biology.

[12]  W. Harris,et al.  Spontaneous assembly of bivalent single chain antibody fragments in Escherichia coli. , 1994, Molecular immunology.

[13]  A. Plückthun,et al.  Tetravalent miniantibodies with high avidity assembling in Escherichia coli. , 1995, Journal of molecular biology.

[14]  L E Williams,et al.  Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. , 1996, Immunotechnology : an international journal of immunological engineering.

[15]  T. Yokota,et al.  Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. , 1991, Cancer research.

[16]  L E Williams,et al.  Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. , 1996, Cancer research.

[17]  J. Schlom,et al.  Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. , 1983, Cancer research.

[18]  S. Hammarström,et al.  Binding of Helix Pomatia A Hemagglutinin to Human Erythrocytes and their Cells. Influence of Multivalent Interaction on Affinity , 1973, Scandinavian journal of immunology.

[19]  G W Beresford,et al.  Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.